Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Pfizer Unit Sues to Block Generic Form of Braftovi Cancer Drug

Sept. 22, 2022, 9:56 PM

Pfizer Inc.’s Array BioPharma Inc. unit alleges a generic version of Braftovi proposed by Aurobindo Pharma Ltd.’s Eugia Pharma Specialties Ltd. infringes a patent for the cancer drug, a federal lawsuit in Delaware says.

According to a complaint filed Thursday in the US District Court for the District of Delaware, Eugia’s copy infringes a patent related to the drug’s compounds and methods of using them in combination with cetuximab to treat metastatic colorectal cancer.

The patent expires in August 2033, the latest expiration of the 13 patents listed for Braftovi in the US Food and Drug Administration’s registry of approved ...